

Amendments to the Specification

At page one, please insert the following section after the Title of Invention, but before the heading “**FIELD OF THE INVENTION**,” page 1, line 5:

Cross Reference to Related Applications

This application is the U.S. National Stage of International Application No. PCT/CA05/00040, filed January 12, 2005, which claims the benefit of the filing date of U.S. Provisional Application Nos. 60/535,496, filed January 12, 2004, and 60/602,817, filed August 18, 2004, hereby incorporated by reference.

Please replace the section regarding Figures 1 to 8 found on page 5, lines 11-26, under the heading “**BRIEF DESCRIPTION OF THE FIGURES**” with the following section:

Figure 1 depicts the anti-proliferative effects of interferon alpha *in vitro* in human renal carcinoma cell lines (Caki-1 and A498);

~~Figure 2~~Figures 2A and 2B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on Caki-1 renal tumour growth in SCID mice;

~~Figure 3~~Figures 3A and 3B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on Caki-1 renal tumour growth in SCID mice;

~~Figure 4~~Figures 4A and 4B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on Caki-1 renal tumour growth in SCID mice;

~~Figure 5~~Figures 5A and 5B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on Caki-1 renal carcinoma growth in SCID mice;

~~Figure 6~~Figures 6A and 6B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on A498 renal carcinoma growth in SCID mice;

~~Figure 7~~Figures 7A and 7B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on A498 renal tumour growth in SCID mice; and

~~Figure 8~~Figures 8A and 8B depicts depict the effects of SEQ ID NO:1 alone and in combination with interferon alpha on A498 renal tumour growth in SCID mice[[.]];.

Please replace the current Sequence Listing, consisting of 28 pages, with the Sequence Listing submitted with the concurrently filed statement under 37 C.F.R. §§ 1.821 through 1.824, and consisting of 26 pages.